<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937948</url>
  </required_header>
  <id_info>
    <org_study_id>2015-02-45-01</org_study_id>
    <nct_id>NCT02937948</nct_id>
  </id_info>
  <brief_title>Adaptative Radiotherapy for Locally Advanced Cervical Cancer</brief_title>
  <acronym>ARCOL</acronym>
  <official_title>Phase II Study of Adaptative Radiotherapy for Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of adaptative Intensity-Modulated Radiation Therapy (IMRT) in
      the treatment of locally advanced cervical cancer on acute genito-urinary (GU), and
      gastrointestinal (GI) toxicities. Every patients will be treated according to the adaptative
      IMRT strategy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient having an Acute genito-urinary (GU) and Gastro-intestinal (GI) toxicities assessed by CTCAE V4.03</measure>
    <time_frame>3 months after end of radio-chemotherapy treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient having a Grade ≥ 2 Hematologic and other toxicities assessed by CTCAE V4.03</measure>
    <time_frame>3 months after end of radio-chemotherapy treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Uterine Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Adaptative Treatment plans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adaptative treatment plan</intervention_name>
    <description>Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an &quot;intermediate&quot; one, one to a full bladder.</description>
    <arm_group_label>Adaptative Treatment plans</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External radiotherapy</intervention_name>
    <description>At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.</description>
    <arm_group_label>Adaptative Treatment plans</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cervix carcinoma proved by histology

          -  According International Federation of Gynecology and Obstetrics (FIGO) classification,
             stages IB2, IIA, IIB, IIIA and IIIB without lumbo-aortic lymph node damage (surgical
             or radiologic)

          -  Patient treated with radio-chemotherapy then curietherapy with curative aim, validated
             in multidisciplinary meeting

          -  Renal, hepatic and cardiovascular functions that allow administration of the
             associated systemic treatment

          -  Older than 18 years

          -  Good general status, World Health Organization less or equal to 1

          -  Signed informed consent

        Exclusion Criteria:

          -  History of cancer that is not controlled and / or treated for less than 5 years
             (excepted for cutaneous baso-cellular cancer)

          -  History of pelvic irradiation

          -  Simultaneous participation to another research that could interfere with the study
             results

          -  Pregnant or breastfeeding patient

          -  Patient under tutor or guardian

          -  Patient not able to respect medical follow-up for geographical, social or
             psychological reasons

          -  Not affiliated to a system of French social security
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Renaud de Crevoisier, Professor</last_name>
    <phone>+33299253031</phone>
    <email>r.de-crevoisier@rennes.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martine Gestin, PhD</last_name>
    <phone>+33299253036</phone>
    <email>m.gestin@rennes.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Mesgouez-Nebout, MD</last_name>
      <phone>+33241352911</phone>
      <email>nathalie.mesgouez-nebout@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Mesgouez-Nebout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nejla Allouache, MD</last_name>
      <phone>+33231455033</phone>
      <email>n.allouache@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Nejla Allouache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine Peignaux, MD</last_name>
      <phone>+33380737518</phone>
      <email>kpeignaux@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Karine Peignaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence Le Tinier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florence Le Tinier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine Racadot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Séverine Racadot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre rené Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magali Leblanc-Onfroy, MD</last_name>
      <phone>+33240679955</phone>
      <email>magali.le-blanc@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Magali Leblanc-Onfroy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Berger, MD</last_name>
      <phone>+33549444485</phone>
      <email>antoine.berger@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud de Crevoisier, Professor</last_name>
      <phone>+33299253031</phone>
      <email>r.de-crevoisier@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud de Crevosier, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Hanzen, MD</last_name>
      <phone>+33232082485</phone>
      <email>chantal.hanzen@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Chantal Hanzen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Barillot, Professor</last_name>
      <phone>+33247474747</phone>
      <email>i.barillot@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Barillot, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Oldrini-Renard, MD</last_name>
      <phone>+33383598534</phone>
      <email>s.renard@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Oldrini-Renard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Haie-Meder, MD</last_name>
      <phone>+33142114211</phone>
      <email>christine.haiemeder@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Haie-Meder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not authorized in France</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

